Digging into the recent data from the MAESTRO-NASH phase 3 trial of Madrigal Pharmaceuticals' resmetirom in NASHTicker(s): MDGL
Institution: Texas Liver Institute
- Medical Director and VP of Research and Development at the Texas Liver Institute and Professor of Medicine at the University of Texas Health San Antonio.
- Manages hundreds of patients with NASH.
- Has authored over 400 peer-reviewed publications in medical journals.
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.